Sarepta (SRPT) on Soars 15.7% on 5th Day Ahead of Clinical Trial Results

Group 1 - Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has seen a significant stock price increase, rising 15.68% to close at $22.35, marking its fifth consecutive day of gains as investors prepare for preliminary results from a clinical trial for a drug targeting myotonic dystrophy type 1 (DM1) [1] - The company plans to announce preliminary results for the first phase of its clinical trial for SRP-1003 in DM1 patients in the second half of the year, alongside other clinical trials for various diseases [2] - Arrowhead Pharmaceuticals, the original developer of SRP-1003, has acquired a $174 million stake in Sarepta through a privately negotiated block sale, indicating strong support for the company's potential [3] Group 2 - Sarepta Therapeutics has entered into an agreement with Arrowhead Pharmaceuticals to transfer 2.66 million shares to settle a $50 million obligation, part of a larger $100 million milestone payment [4]